Kyle Chenet

Kyle Chenet has over 18 years of experience in business development, finance, and strategy. In 2002, they began their career at GlaxoSmithKline as Director of Business Development. In 2005, they joined Biolex as Director of Business Development. In 2007, they moved to Liquidia Technologies as VP of Corporate Development and Director of Business Development. From 2014 to 2016, they were the CEO of Lq3 Pharmaceuticals, a venture-backed biopharma company. During this time, they also served as an Advisor, BD, Finance, and Strategy for Ceres Nanosciences, Inc. In 2016, they founded 410 Medical, Inc. and currently serves as the company's CEO.

Kyle Chenet attended Stanford University Graduate School of Business from 2000 to 2002, where they earned an MBA. Prior to that, they attended the University of Michigan from 1990 to 1995, where they earned a BSE in Mechanical Engineering.